Education
About Us
Working with TipRanks
Follow Us
Irhythm Technologies (IRTC)
NASDAQ:IRTC
Earnings Data
Report Date
Apr 30, 2026After Close (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
-0.62Last Year’s EPS
-0.97Same Quarter Last Year
Strong Buy
Based on 13 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call emphasized strong, volume‑led revenue growth (Q4 +27.1%; FY +26.2%), meaningful margin expansion and several historic profitability and free‑cash‑flow milestones, alongside clear execution on EHR integrations, primary care adoption and AI pilots. Offsetting risks include a delay to next‑gen MCT driven by FDA and gateway changes, ongoing operating expense investments and regulatory/reimbursement uncertainties. Innovative and international channels are early stage and were conservatively treated in guidance. On balance, the company demonstrated durable core growth, expanding profitability and substantial financial flexibility while acknowledging a few timing and execution risks.Company Guidance
Strong Revenue Growth
Q4 2025 revenue of $208.9M, up 27.1% year-over-year; FY2025 revenue of $747.1M, up 26.2% YoY. Fifth consecutive quarter with revenue growth above 20%.
Profitability and Cash Flow Milestones
First positive quarterly net income in company history: Q4 net income $5.6M ($0.17 dil. EPS). Full-year adjusted EBITDA $68.9M (9.2% of revenue) with Q4 adjusted EBITDA $34.3M (16.4% of revenue, +470 bps YoY). Free cash flow of $14.5M in Q4 and $34.5M for FY2025; ended year with $583.8M in cash, cash equivalents and marketable securities.
Margin Expansion
Gross margin improved to 70.9% in Q4 (up 90 bps YoY) and 70.6% for the full year (up 170 bps YoY). Significant adjusted EBITDA margin expansion (Q4 16.4%; FY improvement >1,000 bps YoY).
Market Leadership in Long‑Term Continuous Monitoring
Estimated ~72% share in long-term continuous monitoring (segment growing in the high teens). Supported by clinical credibility: more than 135 scientific publications.
Zio AT Momentum and MCT Platform Positioning
Zio AT unit growth ran more than twice the company average for the year and management stated AT grew north of 50% YoY; MCT market share approximately 15%. Next‑generation MCT (21‑day wear, improved form factor and algorithms) under FDA review with expected commercial release in H1 2027.
Commercial Expansion and EHR Integration
More than one‑third of volume originated in primary care; company serves ~40,000 primary care physicians. Over 50% of volume flows through EHR‑integrated accounts; 75 of top 100 customers fully integrated. Home enrollment ~23% of U.S. volume.
Data and AI Capabilities
Nearly 3 billion hours of curated ECG data and ~13M patients in the database. Early predictive AI pilots (with Lucem Health) reported more than 85% accuracy in pre‑identifying patients with clinically relevant arrhythmias.
International and Adjacent Market Progress
Commercial presence in the U.K., select EU markets and Japan; U.K. delivered the largest quarter of volume to date. Active sleep pilots targeting the ~40M U.S. sleep apnea patients; international markets collectively run ~3M ambulatory cardiac tests annually representing a large long‑term opportunity (current share <1%).
Forward Guidance and Profitability Roadmap
2026 guidance: revenue $870M–$880M (16%–18% growth), gross margin expected to improve ~80–100 bps vs 2025, and adjusted EBITDA margin expected to expand to 11.5%–12.5% for FY2026 (Q1 adj. EBITDA margin 3%–4%).
IRTC Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
IRTC Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 19, 2026 | $158.88 | $150.96 | -4.98% |
Oct 30, 2025 | $184.12 | $187.30 | +1.73% |
Jul 31, 2025 | $140.18 | $164.97 | +17.68% |
May 01, 2025 | $108.59 | $131.12 | +20.75% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Irhythm Technologies (IRTC) report earnings?
Irhythm Technologies (IRTC) is schdueled to report earning on Apr 30, 2026, After Close (Confirmed).
What is Irhythm Technologies (IRTC) earnings time?
Irhythm Technologies (IRTC) earnings time is at Apr 30, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is IRTC EPS forecast?
IRTC EPS forecast for the fiscal quarter 2026 (Q1) is -0.62.